What is Tapemark?
Headquartered in West St. Paul, Minnesota, Tapemark operates as a sophisticated contract manufacturer with a robust portfolio of certifications, including ISO 9001 and 13485, alongside FDA registration for drugs, devices, food, and cosmetics. The company distinguishes itself through integrated technical services such as precision coating, printing, die cutting, and complex packaging. As a critical partner in the medical and consumer product supply chains, Tapemark maintains a rigorous commitment to cGMP compliance, ensuring that its manufacturing processes meet the stringent quality standards required by global healthcare and pharmaceutical enterprises. Its market position is defined by a long-standing reputation for technical innovation and reliable, high-volume production capacity.
How much funding has Tapemark raised?
Tapemark has raised a total of $2M across 1 funding round:
Debt
$2M
Debt (2020): $2M with participation from PPP
Key Investors in Tapemark
PPP
Public-Private Partnership
What's next for Tapemark?
With this major enterprise-level funding, Tapemark is positioned to accelerate its strategic growth initiatives, likely focusing on the modernization of its manufacturing facilities and the enhancement of its proprietary converting technologies. The capital injection provides the necessary liquidity to scale production in response to increasing demand for complex medical components. Moving forward, the firm is expected to prioritize operational efficiency and the expansion of its service offerings, further cementing its role as a preferred manufacturing partner for global brands. By maintaining its focus on quality assurance and regulatory excellence, Tapemark is well-equipped to navigate the evolving complexities of the pharmaceutical and medical device markets, ensuring long-term sustainability and competitive advantage.
See full Tapemark company page
